Trial intelligence / Profile preview

Avapritinib study in indolent systemic mastocytosis

NL-OMON59219Phase 2Active, not recruiting

Sponsor
Blueprint Medicines
Start
Apr 2019
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 2, randomised, double-blind trial of avapritinib in indolent systemic mastocytosis (ISM) (4 arms), sponsored by Blueprint Medicines. Primary endpoints: Recommended phase 2 dose, Change in ISM-SAF total symptom score and 1 more. Started Apr 2019; status: active, not recruiting.

02

Drugs

avapritinib
03

Conditions

indolent systemic mastocytosis (ISM)

Beyond the preview

Go deeper on NL-OMON59219.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NL-OMON59219.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call